Skanda Goudar
About Skanda Goudar
Skanda Goudar is the Director of Alliance Management at Bolt Biotherapeutics, Inc., where he has worked since 2021. He has extensive experience in the biopharmaceutical industry, having held various positions at companies such as Forty Seven, Inc., Gilead Sciences, and Phenomix Corporation.
Work at Bolt Biotherapeutics
Skanda Goudar has been serving as the Director of Alliance Management at Bolt Biotherapeutics, Inc. since 2021. In this role, he is responsible for managing strategic partnerships and collaborations that are crucial for the company's development and growth in the biotherapeutics sector. His position is based in Redwood City, California, where he has contributed to the company's efforts in advancing innovative therapies.
Previous Experience at Forty Seven, Inc.
Prior to his current role, Skanda Goudar worked at Forty Seven, Inc. as Director from 2016 to 2020. During his four years at the company, he focused on alliance management and played a key role in fostering collaborations that supported the company's mission in the field of immuno-oncology.
Career at Gilead Sciences
Skanda Goudar held multiple positions at Gilead Sciences over a span of six years, from 2010 to 2016. He began as a Clinical Program Manager and later advanced to Associate Director of Alliance Management from 2020 to 2022. His experience at Gilead involved overseeing clinical programs and managing strategic alliances that contributed to the company's portfolio.
Education and Expertise
Skanda Goudar earned his MBA in Marketing Management from Loyola Marymount University, College of Business Administration, where he studied from 2000 to 2002. He also holds a Bachelor of Science degree in Pharmaceutical Sciences from Birla Institute of Technology, Mesra, which he completed from 1995 to 1999. His educational background supports his expertise in both business and pharmaceutical sciences.
Early Career at Phenomix Corporation
Skanda Goudar began his career at Phenomix Corporation, where he worked as a Senior Clinical Research Associate from 2008 to 2010. In this role, he was involved in clinical research activities, contributing to the development of innovative therapeutic solutions.